GlassScriptPhysician profile
Amanda Austin
NPI 1407385560
$2,816.89
in general payments reported to CMS, 2019-2025
15 companies · $971 in 2025
The $971 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $270 · 2023: $661 · 2024: $613 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $432.11 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.09 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $398.34 | 2021-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $394.46 | 2021-2025 | Lifevest |
| Pfizer INC. | $351.58 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $251.75 | 2022-2025 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $216.67 | 2022-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $147.65 | 2021-2025 | Wainua, Farxiga, Andexxa |
| Edwards Lifesciences Corporation | $95.63 | 2023-2025 | Evoque |
| Atricure, INC. | $25.25 | 2024 | |
| Kestra Medical Technology Services, INC. | $25.00 | 2025 | Assure Wcd |
| Novo Nordisk INC | $23.47 | 2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $15.36 | 2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2025 | |
| Esperion Therapeutics, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.